Immatics N.V. (IMTX)
| Market Cap | 1.28B +93.6% |
| Revenue (ttm) | 43.00M -74.1% |
| Net Income | -247.21M |
| EPS | -1.97 |
| Shares Out | 136.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 193,396 |
| Open | 9.25 |
| Previous Close | 9.23 |
| Day's Range | 9.10 - 9.44 |
| 52-Week Range | 5.05 - 12.41 |
| Beta | 1.32 |
| Analysts | Strong Buy |
| Price Target | 18.89 (+102.03%) |
| Earnings Date | Aug 12, 2026 |
About IMTX
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy produ... [Read more]
Analyst Summary
According to 9 analysts, the average rating for IMTX stock is "Strong Buy." The 12-month stock price target is $18.89, which is an increase of 102.03% from the latest price.
News
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
Houston, Texas and Tuebingen, Germany , June 1, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage program...
Immatics announces presentation of extended data from Phase 1 trial of IMA401
Immatics (IMTX) announced the presentation of extended data from the ongoing Phase 1 clinical trial evaluating its TCR bispecific candidate IMA401 targeting MAGEA4/8 in heavily pretreated patients wit...
Immatics announces updated Phase 1 data for its Prame TCR T-cell therapy
Immatics (IMTX) N.V. announced updated Phase 1 data for its IMA203CD8 PrameTCR T-cell therapy in gynecologic cancers and synovial sarcoma at the Annual Meeting of the American Society for Clinical…
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
Houston, Texas and Tuebingen , Germany, May 31, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage program...
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expansion trial achieved anti-tumor activity in platinum-resistant ovarian cancer and in uterine cancer wi...
Immatics reports Q1 EPS (43c), consensus (44c)
Reports Q1 revenue $7.61M, consensus $10.41M. “Immatics (IMTX) is entering a pivotal period as we continue to progress toward the pre-specified interim and final analyses from the Phase 3 SUPRAME…
Immatics Announces First Quarter 2026 Financial Results and Business Update
SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggered in 2026, advancing toward the Company's first commercial launch planned in 2027 Multiple key clini...
Immatics Earnings release: Q1 2026
Immatics released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Immatics initiated with a Buy at TD Cowen
TD Cowen initiated coverage of Immatics (IMTX) with a Buy rating and no price target The firm says the company has the most extensive PRAME-targeted pipeline. Immatics’ lead asset is…
Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
Houston, Texas and Tuebingen, Germany, April 21, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage progra...
Immatics abstract accepted for late-breaking poster presentation at AACR meeting
Immatics (IMTX) announced that an abstract highlighting a pediatric patient treated with a PRAME-directed cell therapy using Immatics’ PRAME T-cell receptor has been accepted for a late-breaking poste...
Immatics assumed with a Buy at Jefferies
Jefferies assumed coverage of Immatics (IMTX) with a Buy rating and $18 price target The firm thinks the company is at an inflection point. The company’s cutaneous melanoma readout this…
Immatics sees cash runway into 2028
Cash and cash equivalents, as well as other financial assets, total $551.4 million as of December 31, 2025, compared to $710.3 million as of December 31, 2024. The decrease is…
Immatics reports FY25 EPS (EUR 1.61) vs. EUR 0.14 last year
Reports FY25 reports FY25 revenue EUR 48.3M vs. EUR 155.8M last year. “Following a year of strong execution and data updates across our entire PRAME franchise, Immatics (IMTX) is entering…
Immatics Earnings release: Q4 2025
Immatics released its Q4 2025 earnings on March 5, 2026, summarizing the period's financial results.
Immatics Annual report: Q4 2025
Immatics has published its Q4 2025 annual report on March 5, 2026.
Immatics price target raised to $25 from $23 at Mizuho
Mizuho analyst Graig Suvannavejh raised the firm’s price target on Immatics (IMTX) to $25 from $23 and keeps an Outperform rating on the shares.
Immatics’ treatment of Stage II and higher CM granted FDA orphan designation
Immatics (IMTX)’ treatment of Stage II and higher cutaneous melanoma, in human leukocyte antigen-A 02:01-positive patients, was granted FDA orphan designation, according to a post to the agency’s webs...
Immatics price target raised to $17 from $14 at BofA
BofA analyst Alec Stranahan raised the firm’s price target on Immatics (IMTX) to $17 from $14 and keeps a Buy rating on the shares. The firm is updating its price…
Immatics presents IMA203CD8 PRAME cell therapy data at ESMO-IO Congress
Immatics (IMTX) announced updated Phase 1a dose escalation data from its second-generation PRAME cell therapy, IMA203CD8, in heavily pre-treated patients with solid tumors. Based on the enhanced pharm...
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress
Houston , Texas and Tuebingen, Germany, December 11, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision tar...
Immatics announces offering of 12.5M ordinary shares
Immatics (IMTX) announced that it has agreed to sell 12.5M ordinary shares at $10.00 per share in an underwritten offering. The gross proceeds from the offering, before deducting the underwriting…
Immatics Announces $125 Million Underwritten Offering
Houston, Texas and Tuebingen, Germany, December 05, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision tar...
Immatics price target raised to $23 from $19 at Mizuho
Mizuho raised the firm’s price target on Immatics (IMTX) to $23 from $19 and keeps an Outperform rating on the shares following the Q3 report. The firm upped its probability…
Immatics price target raised to $19 from $16 at Guggenheim
Guggenheim raised the firm’s price target on Immatics (IMTX) to $19 from $16 and keeps a Buy rating on the shares. The firm is updating its model for Q3 results…